Aker BioMarine ASA
Capital Markets Update
1 December 2021 Aker BioMarine AS hosted its Capital Markets Update (CMU) as a fully digital event.
At the event, the executive management provided a deep-dive into the business and explained the plans for growth and value creation. Watch the complete presentation here and download the presentation PDF.
Read more and watch the individual segments below.
Aker BioMarine's Capital Markets Update
Aker BioMarine's Capital Markets Update and 2021 full-year comments
1 December 2021: Today, Aker BioMarine ASA will host its Capital Markets Update (CMU) as a fully digital event at 09:00 CET. The presentation material that will be used is available at www.akerbiomarine.com and is also attached to this release.
At the event, the executive management will provide a deep-dive into the business and will explain the plans for growth and value creation.
The key messages at the CMU
- Aker BioMarine’s ambition is to nearly double revenues towards 2025, with targeted annual growth rate of between 14% and 18%.
- Targeted adjusted EBITDA margin for the group in 2025 of +/- 30%.
- The company plans for average annual krill harvesting volumes of 55,000-60,000 metric tons (MT), although there will be seasonal and operational variations from year to year.
- To deliver on these targets, the company has established new growth- and improvement plans for all operational segments; Offshore, Animal Health & Nutrition, Human Health & Nutrition and for Brands.
- For 2022, the company targets revenue growth of 20%-25% with targeted adj. EBITDA margin of 20%-25%.
“Aker BioMarine has built a strong position in the attractive markets for human and animal nutrition for krill. As a fully integrated producer, we target significant sales growth in all our main segments towards 2025 and we seek improved results and cash flow. Krill harvesting is crucial for the company and with recent investments and measures for improved fisheries, we will lift the average annual harvesting volumes. We have set ambitious targets for the coming years, and it now comes down to execution”, said CEO Matts Johansen.
Operational update and 2021 full-year comments
The new harvesting season has started. Antarctic Endurance started fishing 26 November and has per 30 November produced 500 MT. The other harvesting vessels are on their way to the harvesting grounds, and we expect Saga Sea to start fishing this week and Antarctic Sea to start mid-December. Per 30 November the fleet has produced 41,900 MT so far this year.
Aker BioMarine reiterates the guiding for 2021 with expected annual sales to be somewhat below last year’s revenue of USD 289 million with an expected adjusted EBITDA margin of 15-17%. The company expects harvesting volume for the year to be in the upper part of the communicated range of 40,000-45,000 MT.
The turnaround in sales for Superba is progressing, and in the two first months of this quarter, Aker BioMarine has already sold volumes in line with the full third quarter.
The R&D team in Aker BioMarine has recently finalized three studies on Superba, all with positive results. The studies have been performed in the fields of arthritis, on strength & muscles and on anti-aging. All studies may result in new health claims for Superba. The studies are expected to be published within six months.
CMU program and participation
09:00 CET: Presentations by executive management webcasted at www.akerbiomarine.com.
10:35 CET: Q&A conference call. To participate in the Q&A conference call, please contact the conference call operator at the telephone numbers listed below:
Phone number Norway: +47 2350 2007
Phone number International: +44 (0) 330 336 9125
Confirmation code: 1155264
Please join the event prior to scheduled start time and provide the confirmation code or ask for Aker BioMarine's Capital Markets Update.
For further information, please contact:
Carl Christian Bachke, Investor Relations
Mobile: +47 909 808 48
About Aker BioMarine ASA
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.